| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 topline data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Immunology | ||
Phase 1 topline data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Immunology | ||
Phase 1 topline data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Immunology |
Recent Updates
Recently added Catalysts
Enanta Pharmaceuticals, Inc.$13.7
-0.55 (-3.86%)
C 48Pipeline Score Fair Value Pharma · Commercial
Market Cap
405.64 M
EPS
-2.59
P/E Ratio
-
Value Trade
4.25 M
SEC Financials
Q1 2026Dilution Risk
Revenue
17.16 M
R&D Expenses
19.44 M
Total Assets
314.70 M
Total Liabilities
198.12 M
Equity
116.59 M
D/E Ratio
12,345
2.65 %
Week
4.81 %
1 Month
0.43 %
3 Month
15.48 %
6 Month
-71.6 %
5 Year
-3.86 %
All Time
Cash Data
Cash Position
163.77 M
Monthly Burn
3.95 M
Runway
39.5 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
179.22 K
52 Week Range
5.70 - 17.15
% held by Insiders
5.08 %
% held by Institutions
92.37 %
Enterprise Value
428.49 M
Total Shares
29.01 M
Short %
9.44 %
Float Shares
27.38 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Enanta Pharmaceuticals, Inc.
322Total events
4Upcoming
80Tier-1 (high impact)
2013 – 2026Coverage
Upcoming catalysts 4
Q4 2026
T1Topline Readout
Topline Phase 1 data expected, including biomarker effects on serum tryptase
Event history 318
Q3 2026
●IND SubmissionEPS-3903IND
IND filing for EPS-3903 (oral STAT6 inhibitor)
type 2 inflammatory diseasessource ↗
Q3 2026
●Development Candidate NominationPreclinical
Nomination of MRGPRX2 development candidate
type 2 inflammatory diseasessource ↗
Jun 23, 2026
▲EU ApprovalMAVIRETEx-US Regulatory
European Commission approval of MAVIRET for acute hepatitis C
acute hepatitis C virussource ↗
Jun 18, 2026
▲Trial InitiationzelicapavirTrial
Advancement of zelicapavir clinical development program
Respiratory Syncytial Virus (RSV)source ↗
Jun 10, 2026
Jun 4, 2026
May 16, 2026
◆Oral PresentationPresentation
Presentation of RSV program data at ATS 2026
Respiratory Syncytial Virussource ↗
May 8, 2026
Apr 13, 2026
▲First Patient DosedEDP-978Trial
First participant dosed in Phase 1 clinical trial of EDP-978
Urticariasource ↗
Q2 2026
●Timing GuidancezelicapavirPresentation
Update on development path for zelicapavir pivotal study
RSV infection in adults at high risksource ↗
Mar 10, 2026
◆Oral PresentationPresentation
Management participation in fireside chat at The Citizens Life Sciences Conference
Drug Pipeline Intelligence
C48
Pipeline Score $1.1B
Pipeline ValueFair Value
Valuation Signal17
Drugs Scored2.8x
rNPV / MCap Top 71%
Micro Cap (rank 265 of 912)
Percentile RankEnanta Pharmaceuticals, Inc. carries a moderate pipeline score (48/100), with $2.9B risk-adjusted pipeline value, led by EDP-235 in COVID-19 (Phase 2), across $84B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EDP-235 Small molecule | COVID-19 | Phase 2 | NCT05594615 | 21% | $525M | COMPLETED | 291 | - | - | Nov 18, 2022 | - | Apr 27, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
zelicapavir | Respiratory Syncytial Virus (RSV) | Phase 2b | 2025-11-17 | In the Phase 2b RSVHR study, zelicapavir demonstrated a clinically meaningful reduction in time to complete resolution of RSV symptoms by 2.2 days for the overall efficacy population and 6.7 days for high-risk patients (p<0.001). Read More | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year -Ended Read More | |
zelicapavir | Respiratory Syncytial Virus (RSV) | Phase 2b | 2025-11-17 | In the Phase 2b RSVHR study, zelicapavir demonstrated a clinically meaningful reduction in time to complete resolution of RSV symptoms by 2.2 days for the overall efficacy population and 6.7 days for high-risk patients (p<0.001). Read More | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year -Ended Read More | |
zelicapavir | Respiratory Syncytial Virus (RSV) | Phase 2b | 2025-11-17 | In the Phase 2b RSVHR study, zelicapavir demonstrated a clinically meaningful reduction in time to complete resolution of RSV symptoms by 2.2 days for the overall efficacy population and 6.7 days for high-risk patients (p<0.001). Read More | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year -Ended Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ENTA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ENTA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ENTA▲ +5.2%on this news
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
Enanta Pharmaceuticals' partner, AbbVie, has received approval from the European Commission for MAVIRET® (glecaprevir/pibrentasvir) to treat individuals with acute Hepatitis C virus. This approval is significant as it expands the treatment options available for patients suffering from this condition. The approval highlights the ongoing efforts to combat Hepatitis C effectively.
Read more →ENTAEnanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
Enanta Pharmaceuticals has announced progress in its clinical development program for Zelicapavir, aimed at treating Respiratory Syncytial Virus (RSV). The announcement highlights the company's ongoing efforts in addressing this viral infection. Further details on the program's advancements were not provided in the article.
Read more →ENTAZelicapavir Update
The article provides an overview of the company ENTA, detailing its management team, board of directors, and pipeline, which includes various therapeutic areas such as Hepatitis C and Respiratory Syncytial Virus. It also highlights investor resources and corporate responsibility initiatives. However, it lacks specific updates or news regarding Zelicapavir.
Read more →ENTAEnanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference 2026
Enanta Pharmaceuticals will present at the Jefferies Global Healthcare Conference on June 4, 2026. CEO Jay R. Luly and Chief Product Strategy Officer Tara L. Kieffer will participate in a fireside chat. The event will be accessible via a live webcast, with a replay available for 30 days. Enanta focuses on developing small molecule drugs for viral infections and immunological diseases.
Read more →ENTAEnanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Enanta Pharmaceuticals is scheduled to present at the Jefferies Global Healthcare Conference. The event will provide an opportunity for the company to discuss its latest developments and strategies with investors and industry peers. Further details regarding the presentation have not been disclosed.
Read more →ENTAZelicapavir Reduces Symptom Duration and Hospitalization in a Randomized, Double-Blind, Placebo-Controlled, International, Phase 2 Trial
The Phase 2 trial of Zelicapavir demonstrated a significant reduction in symptom duration and hospitalization rates for patients. Conducted internationally with a randomized, double-blind, placebo-controlled design, the study highlights the potential benefits of this treatment. These findings could have important implications for managing related viral infections.
Read more →ENTAEPS-3903 is a Potent and Selective Oral STAT6 Inhibitor That Blocks Th2 Inflammation in a House Dust Mite-Induced Asthma Mouse Model
EPS-3903 is a newly identified oral inhibitor of STAT6, showing significant potential in blocking Th2 inflammation. This compound was tested in a house dust mite-induced asthma mouse model, demonstrating its effectiveness in managing asthma-related inflammation. The findings suggest a promising avenue for treating asthma and related conditions.
Read more →ENTAEPS-3903, a Potent, Oral STAT6 Inhibitor, Exhibits Preferential Lung and Alveolar Macrophage Distribution with Low Drug–Drug Interaction Potential for the Treatment of Asthma
EPS-3903 is a novel oral STAT6 inhibitor that demonstrates a preferential distribution in lung and alveolar macrophages, making it a promising candidate for asthma treatment. Its low drug-drug interaction potential further enhances its therapeutic profile, positioning it as a significant advancement in asthma management. The findings suggest a targeted approach to treating respiratory conditions.
Read more →ENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
Enanta Pharmaceuticals has reported its financial results for the fiscal second quarter ending March 31, 2026. The report includes key financial metrics and insights into the company's performance during this period. Details regarding revenue, expenses, and future outlook are highlighted, reflecting the company's current standing in the biopharma sector.
Read more →ENTAEnanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
Enanta Pharmaceuticals is set to present data regarding its Respiratory Syncytial Virus and STAT6 inhibitor programs at the upcoming American Thoracic Society International Conference in 2026. The presentation aims to highlight the company's advancements in these therapeutic areas. Further details on the data to be presented have not been disclosed.
Read more →ENTAZelicapavir Demonstrates High Clinical and Functional Barrier Against Antiviral Resistance: Results from a Randomized Double-Blind Placebo-Controlled Pediatric RSV Antiviral Clinical Trial
The article discusses the positive results from a randomized double-blind placebo-controlled trial of Zelicapavir, which demonstrated a high clinical and functional barrier against antiviral resistance in treating pediatric Respiratory Syncytial Virus (RSV). The findings suggest that Zelicapavir could be a promising antiviral option for children affected by RSV.
Read more →ENTAZelicapavir Decreases Symptom Duration, Hospitalization and Viral Load in a Global, Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of High-Risk Adults with RSV
A Phase II trial of Zelicapavir demonstrated its effectiveness in reducing symptom duration, hospitalization rates, and viral load among high-risk adults with RSV. The study was randomized, double-blinded, and placebo-controlled, indicating robust methodology. These results suggest that Zelicapavir could be a valuable treatment option for RSV.
Read more →ENTAPotent STAT6 Inhibitor EPS-3903 Has Excellent Preclinical Pharmacokinetics Enabling Sustained STAT6 Inhibition with Once-Daily Oral Dosing in Humans
ENTA's EPS-3903, a potent STAT6 inhibitor, has demonstrated excellent preclinical pharmacokinetics. This allows for sustained inhibition of STAT6 with a convenient once-daily oral dosing regimen in humans. The findings suggest promising therapeutic potential for this compound in treating related conditions.
Read more →ENTADiscovery and Characterization of a Potent and Selective Oral Inhibitor of STAT6 for the Treatment of Allergic Diseases
The article discusses the discovery and characterization of a new oral inhibitor targeting STAT6, aimed at treating allergic diseases. This development is part of the company's broader pipeline that includes various therapeutic areas. However, specific details about the inhibitor's efficacy or clinical trial results are not provided.
Read more →ENTAEPS-3903 Is a Potent and Selective Oral STAT6 Inhibitor That Blocks Th2 Inflammation in an Ovalbumin Asthma Mouse Model
The article discusses EPS-3903, a potent and selective oral inhibitor of STAT6, which has shown promise in blocking Th2 inflammation in a mouse model of asthma. This development could lead to new therapeutic options for asthma patients. The findings highlight the potential of EPS-3903 in addressing Th2-mediated inflammatory responses.
Read more →ENTAOral STAT6 Inhibitor EPS-3903 Demonstrates Good Preclinical In Vivo Tolerability Without Reactive Metabolites or Metabolic/Safety Liability In Vitro or In Vivo
The article discusses the promising preclinical results of the oral STAT6 inhibitor EPS-3903. It highlights the compound's good tolerability in vivo, with no evidence of reactive metabolites or metabolic and safety liabilities. These findings suggest a favorable profile for EPS-3903 in future clinical development.
Read more →ENTAEnanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
Enanta Pharmaceuticals has initiated a Phase 1 clinical trial for EDP-978, an oral KIT inhibitor aimed at treating chronic urticaria. The trial will assess the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults. With chronic urticaria affecting patients' quality of life, EDP-978 may provide a new treatment option for those resistant to existing therapies. Topline results are expected in Q4 2023.
Read more →ENTAEnanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
Enanta Pharmaceuticals is set to present data on Zelicapavir, an oral, once-daily N-Protein inhibitor aimed at treating Respiratory Syncytial Virus (RSV). This presentation will take place at the ESCMID Global 2026 event. The focus on RSV treatment highlights the ongoing research in antiviral therapies.
Read more →ENTAEnanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
Enanta Pharmaceuticals is set to present data regarding its STAT6 inhibitor program at the upcoming IMMUNOLOGY2026TM conference. This annual meeting is organized by the American Association of Immunologists (AAI). The presentation is expected to highlight advancements in the company's research efforts.
Read more →ENTAEnanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
Enanta Pharmaceuticals will participate in a fireside chat at The Citizens Life Sciences Conference on March 10, 2026. The event will take place in Miami Beach, FL, and will be accessible via a live webcast. Enanta focuses on developing small molecule drugs for viral infections and immunological diseases, with current programs targeting respiratory syncytial virus and inflammatory diseases.
Read more →ENTADiscovery of a Potent and Selective KIT Inhibitor for the Treatment of Mast Cell-Mediated Diseases
The article discusses the discovery of a potent and selective KIT inhibitor aimed at treating mast cell-mediated diseases. This advancement could provide new therapeutic options for patients suffering from these conditions. The development highlights the company's ongoing commitment to innovative treatments in immunology.
Read more →ENTAEDP-978, a Potent KIT Inhibitor, Demonstrated Dose-Dependent Target-Engagement and a Favorable Pharmacokinetic Profile with Once-Daily Dosing Potential in Humans
EDP-978, a potent KIT inhibitor, has demonstrated promising results in human trials. It exhibited dose-dependent target engagement and a favorable pharmacokinetic profile, suggesting the potential for once-daily dosing. This development could lead to effective treatments for conditions related to KIT inhibition.
Read more →ENTAEnanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
Enanta Pharmaceuticals announced that it will present preclinical data for EDP-978, a KIT inhibitor aimed at treating mast cell-mediated Type 2 immune diseases, at the 2026 AAAAI Annual Meeting. The presentations will take place on February 27, 2026, in Philadelphia, PA. Two posters will detail the drug's potency and pharmacokinetic profile.
Read more →ENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
Enanta Pharmaceuticals reported its financial results for the fiscal first quarter ending December 31, 2025, highlighting advancements in its RSV treatment portfolio and immunology pipeline. The company recorded total revenue of $18.6 million, primarily from royalties on AbbVie's MAVYRET. Despite a net loss of $11.9 million, Enanta maintains a strong cash position to support its development programs into fiscal 2029.
Read more →ENTAEnanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Enanta Pharmaceuticals will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. CEO Jay R. Luly will discuss the company's innovative approaches to drug development, particularly in virology and immunology. The event will be accessible via a live webcast, with a replay available for 30 days.
Read more →ENTA▲ +6.3%on this news
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year -Ended
Enanta Pharmaceuticals announced its financial results for the fiscal fourth quarter and year ending September 30, 2025. The company achieved significant progress in its virology and immunology programs, notably with positive data from its Phase 2b RSVHR study. Enanta plans to file an IND for its oral STAT6 inhibitor EPS-3903 in 2026, while maintaining a healthy cash position to fund future operations. Despite a decrease in overall revenue due to declining royalties from AbbVie, the company remains focused on developing treatments for viral and immunological diseases.
Read more →ENTAPost-Exposure Prophylaxis (PEP) of Respiratory Syncytial Virus (RSV) Infection After High-Inoculum RSV Human Challenge: Analysis of a Randomized Double-Blind, Placebo-Controlled Trial of EDP-323, an Oral, Non-Nucleoside Polymerase Inhibitor Antiviral
The article discusses a randomized double-blind, placebo-controlled trial of EDP-323, an oral antiviral aimed at providing post-exposure prophylaxis for Respiratory Syncytial Virus (RSV) infection. The trial focuses on high-inoculum RSV human challenge and evaluates the efficacy of EDP-323 as a non-nucleoside polymerase inhibitor. Details on the trial's outcomes and implications for RSV treatment are highlighted.
Read more →ENTAEDP-323, a First-in-Class, Oral, RSV-Specific, Non-Nucleoside L-Protein Inhibitor Antiviral Rapidly Reduces Total RSV Symptoms, Lower RespiratoryTract RSV Symptoms and Viral Load After Human Viral Challenge
EDP-323, a novel oral antiviral targeting RSV, has shown promising results in reducing symptoms and viral load in patients following a human viral challenge. This first-in-class treatment could offer a new therapeutic option for managing respiratory syncytial virus infections. The rapid efficacy observed in the trials highlights its potential impact on patient care.
Read more →ENTAZelicapavir (EDP-938) Antiviral Treatment is Associated with Shortened Duration of RSV Symptoms in a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial in Children 28 Days to 36 Months of Age
The clinical trial of Zelicapavir (EDP-938) demonstrated a reduction in the duration of RSV symptoms in children aged 28 days to 36 months. This randomized, double-blind, placebo-controlled study indicates a positive outcome for the antiviral treatment, suggesting its potential as an effective option for managing RSV in young patients.
Read more →ENTA▲ +91.9%on this news
Phase 2b Study of Zelicapavir in High-Risk Adults: RSVHR Topline Results
The article discusses the topline results of a Phase 2b study of Zelicapavir in high-risk adults with Respiratory Syncytial Virus (RSV). The study aims to evaluate the efficacy and safety of the treatment. Further details on the results and implications for future studies are anticipated.
Read more →ENTA▲ +91.9%on this newsshared move
This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research and development progra
Enanta Pharmaceuticals has presented forward-looking statements about its business and the development of Zelicapavir for treating Respiratory Syncytial Virus (RSV) in high-risk adults. Initial results suggest a favorable safety profile and a clinically meaningful reduction in symptom duration. However, the future success of Zelicapavir will depend on the outcomes of further studies, emphasizing uncertainty in predictions. The company urges caution regarding reliance on forward-looking statements and acknowledges the existing risks and uncertainties.
Read more →ENTA▲ +91.9%on this newsshared move
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults 6.7-Day Improvement in Time to Complete Resolution
Enanta Pharmaceuticals has reported positive topline results from its Phase 2b study of Zelicapavir for treating Respiratory Syncytial Virus (RSV) in high-risk adults. The study demonstrated a 6.7-day improvement in symptom resolution time in patients with conditions like congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD). Additionally, Zelicapavir showed a significantly lower hospitalization rate compared to placebo and met several secondary endpoints for virology and safety. These findings support the potential of Zelicapavir as a new treatment for RSV in vulnerable adult populations.
Read more →ENTA▲ +5.1%on this news
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union WATERTOWN, Mass.—
Enanta Pharmaceuticals has initiated a patent infringement lawsuit against Pfizer in the Unified Patent Court of the European Union, claiming infringement of European Patent No. EP 4 051 265 related to Pfizer's COVID-19 antiviral, Paxlovid. The European Patent Office recently granted Enanta this patent, enhancing its legal standing. A hearing is expected within 12 months, with possible rulings on damages if infringement is confirmed. However, challenges such as patent validity and extended litigation processes present risks for Enanta.
Read more →ENTA▼ -5.9%on this news
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended
Enanta Pharmaceuticals reported its financial results for the fiscal third quarter ending June 30, 2025, showing a positive trajectory in its development programs. The company announced that it is on track to report topline data from the Phase 2 RSVHR study in September. Enanta's financial health is bolstered by cash and marketable securities amounting to $204.1 million, although it recorded a net loss of $18.3 million for the quarter. The company is advancing its pipeline with new candidates like EPS-1421 to target chronic spontaneous urticaria and is also looking to select a STAT6 development candidate in the latter half of 2025.
Read more →ENTAAntiviral Treatment of RSV in Children: Results of a Randomized, Double-Blind, Placebo-Controlled International Trial of Zelicapavir (EDP-938)
The article discusses the results of a randomized, double-blind, placebo-controlled international trial of Zelicapavir (EDP-938) for the antiviral treatment of Respiratory Syncytial Virus (RSV) in children. The trial's findings are significant for understanding the efficacy of this treatment. However, specific results and implications are not detailed in the provided text.
Read more →ENTA▲ +5.3%on this news
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended
Enanta Pharmaceuticals reported its financial results for the fiscal second quarter ending March 31, 2025, highlighting significant progress in its drug development programs. The company successfully enrolled its target patient count for the Phase 2 RSVHR study of zelicapavir and remains on schedule to share topline data by late Q3 2025. Despite increased net losses compared to the previous year, Enanta reported a solid cash position bolstered by tax refunds, enabling continued investment in its virology and immunology pipelines. The company plans to roll out further programs targeting type 2 inflammatory diseases and expects to announce a lead candidate for the STAT6 program in the second half of 2025.
Read more →ENTAMichael Rhodin
Michael Rhodin, Associate Director of Biology at Enanta, shares his passion for science and the challenges faced in the biopharmaceutical industry. He emphasizes the need for better funding for smaller market diseases and reflects on his journey into biology, inspired by his father's scientific discoveries. Rhodin values engagement within his team and encourages open communication.
Read more →ENTA▲ +5.1%on this news
EDP-323, a First-in-Class, Oral, RSV L-Protein Inhibitor Reduces Disease Severity (Respiratory Mucus Production) and Accelerates Viral Clearance in a Human Viral Challenge Study
EDP-323, an innovative oral RSV L-Protein inhibitor, has demonstrated effectiveness in reducing disease severity and accelerating viral clearance during a human viral challenge study. This first-in-class treatment offers new hope for managing respiratory syncytial virus infections. The results suggest a significant advancement in therapeutic options for RSV.
Read more →ENTAEDP-323, a First-in-Class, Once-Daily, Oral Non-nucleoside L-Protein, Replication Inhibitor Antiviral for the Treatment of RSV: Results from a Phase 2a Human Viral Challenge Study
ENTA has announced results from a Phase 2a human viral challenge study for EDP-323, a novel oral antiviral targeting RSV. The study aims to evaluate the efficacy and safety of this first-in-class, once-daily treatment. Further details on the trial outcomes and implications for RSV treatment were not provided in the article.
Read more →ENTAA Phase-2 Double-Blind Placebo Controlled International Trial of Zelicapavir for Treatment of RSV in Young Children
The article discusses a Phase-2 double-blind placebo-controlled trial of Zelicapavir aimed at treating Respiratory Syncytial Virus (RSV) in young children. The trial is part of a broader pipeline addressing various viral infections. Details about the trial's design and expected outcomes are not provided in the text.
Read more →ENTAIn Vitro Characterization of Respiratory Syncytial Virus Inhibitors
The article provides an overview of the company's focus on various viral infections, including Respiratory Syncytial Virus (RSV). It outlines the company's pipeline and clinical trials related to RSV and other indications. However, specific details about recent developments or findings are not included in the text.
Read more →ENTAEDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: PK and PKPD Results from a Phase 2 Challenge Study in Healthy Participants Infected with RSV
EDP-323, a novel oral L-protein inhibitor, has shown promising results in a Phase 2 challenge study involving healthy participants infected with RSV. This first-in-class treatment is designed for once-daily administration, potentially offering a new therapeutic option for RSV. The study's pharmacokinetic and pharmacodynamic results indicate its efficacy and safety profile.
Read more →ENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended
Enanta Pharmaceuticals reported financial results for its fiscal first quarter ended December 31, 2024, highlighting significant advancements in its respiratory and immunology drug pipelines. The company is on track to release topline results from its Phase 2 study of zelicapavir for RSV in high-risk adults by the third quarter of 2025. With a solid cash position of $216.7 million, Enanta plans to continue developing its RSV compounds and expand its immunology portfolio. Despite a decline in revenue due to lower MAVYRET sales, the company's strategic initiatives position it for potential growth and value creation in the near future.
Read more →ENTA▲ +11.7%on this news
Phase 2 Study of Zelicapavir in Children Topline Results
The article discusses the topline results of a Phase 2 study of Zelicapavir in children. It provides an overview of the study's objectives and the context of the research. However, specific results and implications of the study are not detailed in the provided text.
Read more →ENTA▲ +11.7%on this newsshared move
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) Observed an antiviral effect for the primary
Enanta Pharmaceuticals has announced positive topline results from its first-in-pediatrics Phase 2 study of zelicapavir for treating respiratory syncytial virus (RSV) in children aged 28 days to 36 months. The study indicated a significant antiviral effect, with a 1.4 log decline in viral load observed at Day 5 compared to placebo. Zelicapavir demonstrated a favorable safety profile and was well-tolerated among participants. These promising results suggest the potential for zelicapavir to improve treatment outcomes in this vulnerable pediatric population.
Read more →ENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended
Enanta Pharmaceuticals reported its financial results for the fourth quarter and year ended September 30, 2024, revealing a decline in revenue. The company is focused on advancing its RSV treatment pipeline, with positive results from the EDP-323 study and expects topline data from the RSVPEDs study in December. Additionally, Enanta is expanding its immunology offerings with new development candidates. Despite a net loss for the year, Enanta maintains a robust financial position with significant cash reserves.
Read more →ENTA2024
Enanta Pharmaceuticals has reported positive topline results from its Phase 2 study of Zelicapavir, aimed at treating Respiratory Syncytial Virus (RSV) in pediatric patients. Additionally, the company announced successful outcomes from a Phase 2a human challenge study of EDP-323 in healthy adults infected with RSV. These results highlight the potential of both therapies in addressing RSV infections.
Read more →ENTAJosh Klaene
Josh Klaene, a scientist at Enanta, focuses on drug safety through DMPK. His personal experience with RSV motivated him to join the company. Klaene emphasizes the biopharmaceutical industry's challenge of meeting global healthcare demands. He values meaningful work and enjoys family activities outside of his professional life.
Read more →ENTAEDP-323 Challenge Study Topline Data Results
The article provides an overview of EDP-323 challenge study topline data results. It includes sections on the company's management, pipeline, clinical trials, and investor relations. However, specific results or insights from the challenge study are not detailed in the text provided.
Read more →ENTA▼ -7.6%on this news
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter • Announces Completion of Enrollment of RSVPEDs, a Phase 2 Study of Zelicapavir in Pediatric Respiratory Syncytial Virus (RSV) Patients
Enanta Pharmaceuticals has reported its fiscal third quarter results and announced the completion of enrollment for the RSVPEDs study, focusing on pediatric patients with RSV. The company is positioned to report topline data in Q4 2024 while also progressing with other studies for treatments addressing RSV. Despite a net loss of $22.7 million, Enanta maintains a robust financial foundation with substantial cash reserves. The company is also facing legal challenges related to a patent dispute with Pfizer.
Read more →ENTAThe Small Molecule Inhibitor of SARS-CoV-2 3CLpro EDP-235 Prevents Viral Replication and Transmission in Vivo
EDP-235, a small molecule inhibitor targeting SARS-CoV-2 3CLpro, has shown effectiveness in preventing viral replication and transmission in vivo. This development highlights the potential of EDP-235 as a therapeutic option against COVID-19. The results suggest a significant advancement in the fight against the virus.
Read more →ENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET • Anticipates Reporting Topline Data from EDP-323 Respiratory Syncytial Virus (
Enanta Pharmaceuticals announced its financial results for the fiscal second quarter ended March 31, 2024, reporting a net loss of $31.2 million. The company is poised to report topline data from its EDP-323 and Zelicapavir studies, targeting RSV in pediatric patients, with significant updates expected throughout 2024. Enanta has a robust cash position of $300.3 million, allowing it to fund ongoing research and development projects. The company is also advancing toward selecting a development candidate for Chronic Spontaneous Urticaria treatments by late 2024.
Read more →ENTA▲ +7.1%on this news
Efficacy and Safety of EDP-235 in Nonhospitalized Adults With Mild or Moderate COVID-19: Results From the Phase 2 SPRINT Study
The Phase 2 SPRINT study evaluated the efficacy and safety of EDP-235 in nonhospitalized adults with mild or moderate COVID-19. Results demonstrated promising efficacy and a favorable safety profile, suggesting potential for EDP-235 as a treatment option for this patient population. Further studies may be warranted to confirm these findings.
Read more →ENTA▲ +11.1%on this news
Phase 1 Trial of the Safety, Pharmacokinetics, and Antiviral Activity of EDP-514 in Untreated Viremic Chronic Hepatitis B Patients
The article discusses a Phase 1 trial evaluating the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients. The trial aims to assess the drug's potential effectiveness and safety profile in this patient population. Further details about the trial's design and outcomes are not provided in the article.
Read more →ENTA2023
Enanta Pharmaceuticals has reported positive topline results from its Phase 2 SPRINT trial evaluating EDP-235 in standard risk COVID-19 patients. Additionally, the company announced favorable data from a Phase 1 clinical study of EDP-323, an oral L-Protein inhibitor for respiratory syncytial virus. Furthermore, EDP-323 has received FDA Fast Track Designation, enhancing its development prospects.
Read more →ENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended
Enanta Pharmaceuticals reported its financial results for the fiscal fourth quarter and year ended September 30, 2023, highlighting a net loss of $28.1 million for the quarter. The company initiated a Phase 2a challenge study for EDP-323 to treat RSV and reassessed its R&D and G&A spending for 2024, aiming to improve financial stability. Cash and marketable securities totaled $370 million, providing a strong foundation for ongoing operations as the company progresses its clinical programs targeting RSV.
Read more →ENTAEDP-938, A Respiratory Syncytial Virus Antiviral, Demonstrates a High Barrier to Resistance in a Human Challenge Study
EDP-938, an antiviral for Respiratory Syncytial Virus (RSV), has shown a high barrier to resistance in a recent human challenge study. The results indicate that EDP-938 could be a promising treatment option for RSV, demonstrating effective antiviral properties. This development is significant for addressing RSV infections, particularly in vulnerable populations.
Read more →ENTAEDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results from a Phase 1 Study in Healthy Subjects and Correlation with In Vitro Antiviral Activity
EDP-323, an oral L-protein inhibitor, has shown positive results in a Phase 1 study for treating respiratory syncytial virus (RSV). The study involved healthy subjects and demonstrated a favorable safety profile. Additionally, the in vitro antiviral activity of EDP-323 aligns with the clinical outcomes observed in the trial.
Read more →ENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET • Reported Positive Topline Data from Phase 1 Study of EDP-323, an L-Protein Inh
Enanta Pharmaceuticals reported positive topline data from its Phase 1 study of EDP-323, an oral L-protein inhibitor for RSV. The company plans to initiate a Phase 2 human challenge study for EDP-323 in early Q4 2023. Financially, Enanta posted a net loss of $39.1 million for the third quarter, although it maintains a robust cash position of $392.5 million. The ongoing development in their RSV and COVID-19 therapeutic programs demonstrates the company’s commitment to addressing viral infections amidst rising operational expenses.
Read more →ENTACompany Logo Corporate Presentation
Enanta Pharmaceuticals presented its corporate overview highlighting its strong financial position and promising pipeline for antiviral therapies. The presentation focuses on EDP-938, an N-Protein Inhibitor for RSV, which has shown significant antiviral efficacy in clinical studies. However, it also notes that one of its clinical studies did not meet its primary endpoint, indicating a mixed outlook for ongoing trials. The company emphasizes its proven track record in drug discovery and solid balance sheet to support future development efforts.
Read more →ENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET • Reported Positive Topline Data from Phase 2 SPRINT Clinical Study of EDP-235,
Enanta Pharmaceuticals reported its fiscal second quarter financial results, revealing a net loss of $37.7 million. The company highlighted positive topline data from its Phase 2 SPRINT study of EDP-235, a COVID-19 treatment, and announced plans to advance its RSV treatment program with the upcoming Phase 1 data on EDP-323. Additionally, Enanta has enhanced its balance sheet through a $200 million royalty sale, ensuring funding for continued development of its pipeline. Despite the promising developments, the company incurred higher expenses, contributing to its increasing net loss.
Read more →ENTAEnanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET (U.S.)/MAVIRET (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million Non-Dilutive and Strengt
Enanta Pharmaceuticals has announced the sale of 54.5% of its future royalty payments from MAVYRET/MAVIRET to OMERS Life Sciences for $200 million. This sale will begin generating royalty payments in July 2023 and run through June 2032, with total payments capped at 1.42 times the purchase price. Enanta retains 45.5% of royalties until the cap is reached. The funding provides Enanta with increased financial flexibility to support its development of treatments for viral infections.
Read more →ENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2019 Webcast and Conference Call Today at 4:30 p.m. ET WATERTOWN, Mass., February 6, 2020 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-foc
Read more →ENTAEnanta Pharmaceuticals Reports Financial Results for its Fourth Quarter and Year Ended
Enanta Pharmaceuticals Reports Financial Results for its Fourth Quarter and Year Ended Webcast and Conference Call today at 4:30 p.m. ET WATERTOWN, Mass., November 20, 2017 - Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a chemistry-driven biotechnology company dedicated to creat
Read more →ENTACORRECTING and REPLACING Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended
CORRECTING and REPLACING Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2017 CORRECTION...by Enanta Pharmaceuticals, Inc. WATERTOWN, Mass.--(BUSINESS WIRE)-- Seventh paragraph, second sentence of release dated May 8, 2017, should
Read more →ENTAEnanta Pharmaceuticals Announces Highlights of Business Overview and Update on its Research and Development Programs to be Presented at the 35 th Annual J.P. Morgan Healthcare Conference Enanta to p
Enanta Pharmaceuticals Announces Highlights of Business Overview and Update on its Research and Development Programs to be Presented at the 35th Annual J.P. Morgan Healthcare Conference WATERTOWN, Mass., January 6, 2017 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
Read more →ENTAEnanta Announces U.S. Food and Drug Administration Approves AbbVie s VIEKIRA PAK (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C Vi
Enanta Announces U.S. Food and Drug Administration Approves AbbVie s VIEKIRA PAK (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C Virus WATERTOWN, Mass., December 19, 2014 Enanta Pharmaceuticals, Inc., (NASDAQ: E
Read more →ENTAEnanta Pharmaceuticals Announces New Drug Application Submission to the U.S. FDA for All- Oral, Interferon-Free Hepatitis C Regimen Filing Triggers Milestone Payment to Enanta AbbVie s submission to
Enanta Pharmaceuticals Announces New Drug Application Submission to the U.S. FDA for All- Oral, Interferon-Free Hepatitis C Regimen Filing Triggers Milestone Payment to Enanta April 22, 2014 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotech
Read more →ENTAPEARL-III Study Results in Patients with Chronic Hepatitis C Presented at the 21 st Conference on Retroviruses and Opportunistic Infections (CROI) High SVR 12 rates of 99 percent achieved in patient
PEARL-III Study Results in Patients with Chronic Hepatitis C Presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI) WATERTOWN, Mass., March 3, 2014 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced that detailed results from the PEARL-III
Read more →ENTAEnanta Pharmaceuticals Announces Results from Four All-Oral, Interferon-Free, Phase 3 Studies for the Treatment of Genotype 1 Hepatitis C Virus infection - Results confirm previously reported data i
Enanta Pharmaceuticals Announces Results from Four All-Oral, Interferon-Free, Phase 3 Studies for the Treatment of Genotype 1 Hepatitis C Virus infection WATERTOWN, Mass., January 31, 2014 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced results from the PEARL-II, PEA
Read more →ENTAEnanta Pharmaceuticals Announces 96 Percent SVR 12 in Treatment Experienced Genotype 1 hepatitis C Patients in SAPPHIRE-II Study - Second of Six All-Oral, Interferon-Free Phase 3 Hepatitis C Studies
Enanta Pharmaceuticals Announces 96 Percent SVR12 in Treatment Experienced Genotype 1 hepatitis C Patients in SAPPHIRE-II Study - Second of Six All-Oral, Interferon-Free Phase 3 Hepatitis C Studies Using Regimen Containing ABT-450 WATERTOWN, Mass., December 10, 2013 Enanta Pha
Read more →ENTAEnanta Pharmaceuticals Reports Financial Results for the Fiscal Fourth Quarter and Year Ended
Enanta Pharmaceuticals Reports Financial Results for the Quarter and Year Ended September 30, 2013 WATERTOWN, Mass., November 25, 2013 Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule dru
Read more →ENTAEnanta Pharmaceuticals Announces 96 Percent SVR 12 in SAPPHIRE-I Study First of Six All-Oral, Interferon-Free Phase 3 Hepatitis C Studies Using Regimen Containing ABT-450
Enanta Pharmaceuticals Announces 96 Percent SVR12 in SAPPHIRE-I Study First of Six All-Oral, Interferon-Free Phase 3 Hepatitis C Studies Using Regimen WATERTOWN, Mass., November 18, 2013 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced results from the SAPPHIRE-I stu
Read more →ENTAEnanta Pharmaceuticals Reports Financial Results for the Third Fiscal Quarter and Nine Months Ended
Enanta Pharmaceuticals Reports Financial Results for the Quarter and Nine Months Ended June 30, 2013 WATERTOWN, Mass., August 12, 2013 Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule dr
Read more →ENTAEnanta Pharmaceuticals Announces Financial Results for the Second Fiscal Quarter and Six Months Ended
Enanta Pharmaceuticals Announces Financial Results for the Quarter and Six Months Ended March 31, 2013 WATERTOWN, Mass., May 8, 2013 Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drug
Read more →Competitive Position
How ENTA ranks across every disease it competes inCompetitive Position is a premium feature
See how ENTA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial